Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Quanta Services Inc (PWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Quanta Services Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Quanta Services Inc trades at $665.21 (market cap $98.56B). The key difference: Quanta Services Inc is far larger — about 22× ACADIA Pharmaceuticals Inc.'s market cap, and Quanta Services Inc pays a 0.07% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PWR | |
|---|---|---|
Market Cap | $4.49B | $98.56B |
Sector | Health | Industrials |
52-Week High | $28.06 | $785.24 |
52-Week Low | $20.06 | $372.50 |
Enterprise Value | $3.69B | $104.51B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Quanta Services (PWR) trades at $656.79, down 1.72% amid bearish technical signals, though it maintains strong analyst support with 27 buy ratings. The company shows robust revenue growth, reaching $28.48B in 2025, with consistent earnings beats in recent quarters. However, premium valuation metrics including a P/E of 92.46 and EV/EBITDA of 39.58 present challenges. Recent news highlights infrastructure demand drivers but questions valuation sustainability after a 79% yearly gain.
PWR's outlook is supported by record backlog and infrastructure spending tailwinds, but execution risks and high valuation create near-term headwinds. The consensus price target of $842.67 suggests 28% upside potential, though investors must weigh growth prospects against current premium multiples and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
